PDL BioPharma Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
PDL BioPharma (PDLI) Reports Q3 EPS of $0.18
November 6, 2018 5:16 PM ESTPDL BioPharma (NASDAQ: PDLI) reported Q3 EPS of $0.18, versus $0.14 reported last year. Revenue for the quarter came in at $67.9 million versus $62.75 million last year.
For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.
... More